Astrazeneca Pharma India Ltd vs Jfl Life Sciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8236 as of 04 May 10:34 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 80.7 on March 2021 to 185.9 on March 2025 . This represents a CAGR of 18.16% over 5 yearsThe P/E Ratio of JFL Life Sciences Ltd changed from 12.9 on March 2023 to 13.9 on March 2025 . This represents a CAGR of 2.52% over 3 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 7525 crore on March 2021 to ₹ 21515 crore on March 2025 . This represents a CAGR of 23.38% over 5 yearsThe Market Cap of JFL Life Sciences Ltd changed from ₹ 36.29 crore on March 2023 to ₹ 57.58 crore on March 2025 . This represents a CAGR of 16.63% over 3 years The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 618.18 crore as compare to the Sep '25 revenue of ₹ 565.26 crore. This represent the growth of 9.36% The revenue of JFL Life Sciences Ltd for the Dec '25 is ₹ 26.85 crore as compare to the Sep '25 revenue of ₹ 29.92 crore. This represent the decline of -10.26% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 51.44 crore as compare to the Sep '25 ebitda of ₹ 76.06 crore. This represent the decline of -32.37% The ebitda of JFL Life Sciences Ltd for the Dec '25 is ₹ 3.36 crore as compare to the Sep '25 ebitda of ₹ 2.93 crore. This represent the growth of 14.68% The net profit of Astrazeneca Pharma India Ltd changed from ₹ -11.79 crore to ₹ 32.59 crore over 7 quarters. This represents a CAGR of NaN% The net profit of JFL Life Sciences Ltd changed from ₹ 1.91 crore to ₹ 2.02 crore over 7 quarters. This represents a CAGR of 3.25% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of JFL Life Sciences Ltd changed from 8.33 % on March 2024 to 0 % on March 2025 . This represents a CAGR of -100.00% over 2 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About JFL Life Sciences Ltd

JFL Life Sciences Limited was incorporated as JFL Life Sciences Private Limited' on April 25, 2010 as a Private Limited Company.
Pursuant to a Special Resolution held on February 10, 2022, Company converted from a Private Limited to Public Limited Company and name of the Company was changed to JFL Life Sciences Limited', on March 3, 2022.
The Company manufactures and market pharmaceutical products.
The major products are Dry powder injections, Tablets & Capsules (B-Lactam) solid oral dosage form, Tablet and capsules (General) and Oral Rehydration Solutions (ORS). In August 2022, the Company launched an IPO of 29,78,000 Equity Shares by raising funds aggregating to Rs. 18.16 Crore. The Company export products to African countries, Middle Eastern countries and CIS countries, mainly through merchant exporters.

FAQs for the comparison of Astrazeneca Pharma India Ltd and JFL Life Sciences Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or JFL Life Sciences Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,543 Cr while Market cap of JFL Life Sciences Ltd is 62 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and JFL Life Sciences Ltd?

The stock performance of Astrazeneca Pharma India Ltd and JFL Life Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and JFL Life Sciences Ltd?

As of May 4, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8217.2. On the other hand, JFL Life Sciences Ltd stock price is INR ₹9.4.

How do dividend payouts of Astrazeneca Pharma India Ltd and JFL Life Sciences Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and JFL Life Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.